Jean-Jacques Bienaimé

Chief Executive Officer & President at BioMarin Pharmaceutical, Inc.

Jean-Jacques Bienaimé

Jean-Jacques Bienaimé

Chief Executive Officer & President at BioMarin Pharmaceutical, Inc.

Overview
Career Highlights

BioMarin Pharmaceutical, Inc.
Biotechnology Innovation Organization
Genencor International

RelSci Relationships

3210

Number of Boards

19

Birthday

1954

Age

67

Relationships
RelSci Relationships are individuals Jean-Jacques Bienaimé likely has professional access to. A relationship does not necessarily indicate a personal connection.

Chief Executive Officer, Roche Pharmaceuticals at Genentech, Inc.

Relationship likelihood: Strong

Chairman, President & Chief Executive Officer at Incyte Corp.

Relationship likelihood: Strong

Founder at Biotechnology Innovation Organization

Relationship likelihood: Strong

Chief Executive Officer at Roche Holding AG

Relationship likelihood: Strong

Chief Financial & Information Technology Officer at Roche Holding AG

Relationship likelihood: Strong

Senior Vice President & General Counsel at Genentech, Inc.

Relationship likelihood: Strong

Founder at Genentech, Inc.

Relationship likelihood: Strong

Senior Vice President, Secretary & Chief Compliance Officer, Head of Legal Affairs, North America at Genentech, Inc.

Relationship likelihood: Strong

Director at Labcyte, Inc.

Relationship likelihood: Strong

Venture Partner at Pappas Capital LLC

Relationship likelihood: Strong

Paths to Jean-Jacques Bienaimé
Potential Connections via
Relationship Science
You
Jean-Jacques Bienaimé
Chief Executive Officer & President at BioMarin Pharmaceutical, Inc.
Education
M.B.A.
Class of 1980

The Wharton School is the business school of the University of Pennsylvania, an Ivy League university in Philadelphia, Pennsylvania. Wharton was the world’s first collegiate business school and the first business school in the United States. It was established in 1881 through a donation of Joseph Wharton.

Economics
Class of 1976

ESCP Europe is a business school with campusses in Paris, London, Berlin, Madrid, and Turin. Established in 1819, it is the oldest business school in the world. Established on 1 December in 1819, ESCP Europe was founded by a group of economic scholars and businessmen including the economist Jean-Baptiste Say and the trader Vital Roux. ESCP Europe is the oldest business school in the world.

Undergraduate Degree

The University of Texas at Austin is one of the largest public universities in the United States and is the largest institution of The University of Texas System. Founded in 1883, the university has grown from a single building, eight teachers, two departments and 221 students to a 350-acre main campus with 17 colleges and schools, about 24,000 faculty and staff, and more than 50,000 students.

Career History
Chief Executive Officer & President
2005 - Current

About BioMarin BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; KUVAN® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase III clinical development for the treatment of MPS IVA, PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU, BMN-701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/II clinical development for the treatment of Pompe disease, and BMN-673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase I/II clinical development for the treatment of genetically-defined cancers and BMN-111, a modified C-natriuretic peptide, which is currently in Phase I clinical development for the treatment of achondroplasia.

Marketing Director
Current

Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer, Kenneth B. Lee and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA.

Advisor
Current

BB BIOTECH VENTURES is a healthcare-dedicated venture capital fund, focused on companies that develop and market drugs and medical devices. The Guernsey–based fund is advised by the Bellevue Asset Management Group, which has operations in Curaçao, Boston/USA and Kusnacht/Zurich, Switzerland. BB BIOTECH VENTURES has a dedicated team of investment advisors and an advisory board. In addition, it is supported by all of the Group’s health care investment experts, and an extensive network of specialists and advisors. Our goal is to maximize the returns to our investors. To achieve this goal, we combine hard working, experience, networking, and focus on value creation.

Boards & Committees
Member, Advisory Board
Current

Bellevue Asset Management (Venture Capital) is an active manager which invests primarily in private companies developing and marketing drugs and medical devices or providing healthcare services. The investment focus is on the US and Europe. The firm typically invests USD 7-15 million over an investee companies' lifetime, seeking to invest in companies with entrepreneurial individuals/teams, the ability to attain milestones in a timely manner, an advanced clinical pipeline, a proven technology base, good commercialization potential, growing markets, a medical need, significant competitive advantages, barriers to entry and a clear path to liquidity.It generally co-invests in syndicates with other venture capital firms, both leading the syndicate and acting as an active co-investor. It normally seeks representation on the boards of their portfolio companies, partnering with management to create value. The firm typically holds an investment for three to five years.

Member, Advisory Board
Current

BB BIOTECH VENTURES is a healthcare-dedicated venture capital fund, focused on companies that develop and market drugs and medical devices. The Guernseybased fund is advised by the Bellevue Asset Management Group, which has operations in Curaao, Boston/USA and Kusnacht/Zurich, Switzerland. BB BIOTECH VENTURES has a dedicated team of investment advisors and an advisory board. In addition, it is supported by all of the Group's health care investment experts, and an extensive network of specialists and advisors. Our goal is to maximize the returns to our investors. To achieve this goal, we combine hard working, experience, networking, and focus on value creation.

Director
Prior - 2009

Saegis Pharmaceuticals, Inc. developed drug therapeutics. Its phase II SGS742 clinical drug treated diseases such as mild cognitive impairment and attention deficit hyperactivity disorder. Its second SGS742 clinical trial provided coronary artery bypass surgery. The company was founded in 1999 and was headquartered in Half Moon Bay, CA.

Transactions
Details Hidden

BioMarin Pharmaceutical, Inc. issued USD Common Stock

Details Hidden

BioMarin Pharmaceutical, Inc. purchases ZyStor Therapeutics, Inc.

Details Hidden

BioMarin Pharmaceutical, Inc. purchases LEAD Therapeutics, Inc.

Investments
Details Hidden

Safegraph, Inc. builds and maintains data sets to help accelerate machine learning and AI. The company is headquartered in San Francisco, CA.

Details Hidden

Vital Therapies, Inc. operates as a biotherapeutic company, which develops a cell-based therapy targeting the treatment of acute forms of liver failure. Its product candidate, ELAD System, is a human cell-based bio-artificial liver support system that operates outside the body or extracorporeal. The company was founded in May 2003 and is headquartered in San Diego, CA.

Public Holdings
Restricted data only for RelSci Professional users.
Advisors
Special Advisor

Special Advisor to the Chairman & Chief Executive Officer at BioMarin Pharmaceutical, Inc.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Jean-Jacques Bienaimé. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Jean-Jacques Bienaimé's profile does not indicate a business or promotional relationship of any kind between RelSci and Jean-Jacques Bienaimé.